FluoGuide has received green light to proceed to the next dose level with FG001 in the ongoing clinical phase I/II trial in patients undergoing surgical treatment of high grade glioma.

Copenhagen, Denmark, 18 May 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee has reviewed the data from the fifth dose level and approved initiation of the next dose level. In addition, the company has received approval to commence with an evening dosing of the fifth dose level with FG001.

The release as fetched from its publisher. fluoguide.com ↗